Abstract 1891
Background
nab-P monotherapy is approved for 2L treatment (Tx) of MBC. This real-world analysis evaluated comparative effectiveness of 2L nab-P vs Pac in pts with MBC.
Methods
A retrospective cohort study was performed using fully de-identified data from a US electronic medical record platform of 1300 community (non-university based) oncologists. This analysis included pts with MBC who initiated 2L nab-P or Pac monotherapy from 12/1/10 to 4/6/15 (≥ 2 doses of nab-P or Pac required to be included in the analysis). The primary objectives were time to Tx discontinuation (TTD) and time to next Tx (TTNT). Adverse events (AEs) and supportive care were also examined. Subanalyses in pts with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) or triple-negative (TN) MBC were conducted.
Results
This analysis included 411 pts (109 treated with nab-P Tx and 302 with Pac Tx). Pts treated with nab-P were older (mean 61 vs 57 y) and more frequently had HR+ (78% vs 65%) or HER2− (83% vs 70%) disease. Most pts received weekly Tx (Table). Prior use of a taxane or concurrent use of a targeted agent was similar between groups. nab-P was associated with significantly longer TTD vs Pac. TTNT was similar between groups. Pts treated with nab-P had less fatigue, pain, and neuropathy but more nausea and vomiting vs Pac. Antiemetics (IV) and Tx for hydration and allergic reaction were used less with nab-P, and Tx for bone loss and granulocyte colony-stimulating factor (G-CSF) were used less with Pac. In subgroup analyses, TTD was significantly longer with nab-P vs Pac in pts with HR + /HER2− or TN MBC, and TTNT was numerically longer with nab-P vs Pac in pts with HR + /HER2− MBC.
nab-P n = 109 | Pac n = 302 | Unadjusted P-value | Adjusted P-value | |||
---|---|---|---|---|---|---|
Overall population | ||||||
Tx schedule, weekly, n (%) | 90 (83) | 286 (95) | - | - | ||
TTD, median, mos | 4.5 | 2.8 | < 0.001 | < 0.001 | ||
TTNT, median, mos | 5.9 | 4.2 | 0.014 | 0.214 | ||
Any grade AE in > 5% pts, % | ||||||
Overall | 45.0 | 58.3 | 0.017 | 0.032 | ||
Anemia | 26.6 | 36.8 | 0.055 | 0.050 | ||
Neutropenia | 15.6 | 10.6 | 0.167 | 0.245 | ||
Neuropathy | 4.6 | 13.6 | 0.011 | 0.039 | ||
Pain | 1.8 | 12.3 | 0.002 | - | ||
Thrombocytopenia | 7.3 | 3.0 | 0.087 | - | ||
Nausea + Vomiting | 9.2 | 3.0 | 0.008 | - | ||
Diarrhea | 2.8 | 7.0 | 0.109 | - | ||
Dehydration | 6.4 | 3.0 | 0.145 | 0.467 | ||
Infection | 0.9 | 6.3 | 0.025 | 0.059 | ||
Fatigue | 0.5 | 5.6 | 0.001 | 0.023 | ||
Hypersensitivity | 0.0 | 5.6 | 0.009 | - | ||
Supportive Care doses/pt/100 days | ||||||
Antimetics | 5.91 | 8.49 | ConclusionsIn this retrospective review, 2L nab-P was associated with significantly longer TTD vs Pac. Pts treated with nab-P had fewer AEs overall. A similar trend in favor of nab-P was shown in pts with HR + /HER2− or TN MBC. Clinical trial identificationThis study is a retrospective analysis, therefore the protocol number and release data is not applicable. Legal entity responsible for the studyMonika Parisi FundingCelgene Corporation DisclosureC. Pelletier, M. Parisi, S. Glück, Q. Ni: Employee of Celgene Corporation. F. Braiteh: AbbVie, ActiveBiotech, Amgen, AstraZeneca, Bayer, BMS, BIND, BioMarin, BioTheranostics, BN Therapeutics, BI, Caris, Celgene, Daiichi, Dendreon, Genomic Health, Gilead, GSK, Halozyme, Heron, Eli Lilly, Incyte, Insys, Novartis, Pfizer. Resources from the same session2354 - The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institutionPresenter: Seung Tae Kim Session: Poster Display Resources: Abstract 2594 - Neuroendocrine carcinomas of the colorectal origin - Polish experiencePresenter: Agnieszka Kolasińska-Ćwikła Session: Poster Display Resources: Abstract 2539 - Neuroendocrine neoplasms of the appendix including goblet cell carcinoidsPresenter: Agnieszka Kolasinska-Cwikla Session: Poster Display Resources: Abstract 1245 - Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendixPresenter: Amir Mehrvarz Sarshekeh Session: Poster Display Resources: Abstract 3902 - Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET)Presenter: Riccardo Marconcini Session: Poster Display Resources: Abstract 3882 - Differential clinical and pathological characteristics of hereditary neuroendocrine pancreatic tumours (NEPT)Presenter: Gema Marín Zafra Session: Poster Display Resources: Abstract 2296 - Natural course of thyroid cancer nodules compared with benign thyroid nodulesPresenter: Kyung-Jin Yun Session: Poster Display Resources: Abstract 4083 - Reassessment of proliferative activity at disease progression in neuroendocrine neoplasmsPresenter: Noemi Cicchese Session: Poster Display Resources: Abstract 3866 - 18F-FDG-PET to predict disease progression in advanced digestive neuroendocrine neoplasmsPresenter: Maria Rinzivillo Session: Poster Display Resources: Abstract 3651 - UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE studyPresenter: John Ramage Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|